UCLA researchers have successfully grown miniature lungs from stem cells—complete with their own functioning blood vessel ...

RAHWAY, NJ, USA I July 02, 2025 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Pulmonary rehabilitation is initiated and completed by a greater proportion of patients with IPF vs COPD or other chronic respiratory disorders.

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted priority review for its request ...

Remodeling in de novo atherosclerosis, ranging from enlargement to shrinkage, has previously been demonstrated. 123 In contrast to enlargement, shrinkage of an atherosclerotic artery enhances arterial ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

A new statement from leading heart and blood vessel experts in Europe is providing clinical guidance for treatments to ...

If you are diagnosed with pulmonary hypertension (PH) or your doctor suspects PH, it is important for you to see a specialist. Pulmonary arterial hypertension (PAH) is a rare, progressive lung disease ...

BMPER attenuated PI3K/AKT signaling and suppressed BMP4-driven smooth muscle activation in models of PAH. BMPER overexpression mitigated the vascular remodeling that characterizes pulmonary arterial ...

Pulmonary arterial hypertension (PAH) is a vascular remodeling disease that pathologically increases pulmonary vascular resistance. Ultimately, this leads to right ventricular failure and ...

Pulmonary artery aneurysm (PAA) is an infrequent abnormality of the pulmonary vasculature with an unclear natural history and pathogenesis. 1 It represents around 1% of all aneurysms in the thoracic ...